8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Jul 24, 2007)

Filed July 24, 2007For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) filed an 8-K on July 24, 2007, to report its financial results for the second quarter ended June 30, 2007. The primary purpose of this filing was to incorporate by reference the company's press release detailing these results. Investors should refer to the furnished press release (Exhibit 99.1) for specific financial performance data, including revenue, earnings, and any relevant operational updates or guidance for the period. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification mechanism for the release of this crucial information. The press release is expected to cover the company's performance in key therapeutic areas and may provide insights into the sales of its major products, such as AVONEX and RITUXAN, as well as any developments in its product pipeline. Investors are advised to review the press release for a comprehensive understanding of Biogen Idec's financial condition and operational results for the reported quarter.

Key Highlights

  • 1Biogen Idec announced its Q2 2007 financial results on July 24, 2007.
  • 2The 8-K filing incorporates by reference the company's press release dated July 24, 2007, which contains the detailed financial results.
  • 3Investors need to review Exhibit 99.1 (the press release) for specific earnings and operational performance data.
  • 4The filing is made under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
  • 5The information furnished in the press release is not deemed "filed" under Section 18 of the Exchange Act.
  • 6This report serves as a notification of the release of important financial information for the quarter ended June 30, 2007.

Frequently Asked Questions

The detailed financial results for the three months ended June 30, 2007, are provided in the press release furnished as Exhibit 99.1 to this 8-K filing. You should refer to that document for specific figures on revenue, net income, and other financial metrics.

This 8-K filing officially announces that Biogen Idec has released its quarterly financial results. It directs investors to the accompanying press release, which contains the critical performance data and operational updates they need to assess the company's financial health and prospects.

This 8-K filing itself does not contain forward-looking guidance. Such information, if provided, would be detailed within the press release (Exhibit 99.1) that is incorporated by reference. Investors should carefully read the press release for any updates or reaffirmations of future financial expectations.

The statement that the press release is furnished and not deemed 'filed' means that while it contains important information, it does not carry the same legal liabilities under Section 18 of the Securities Exchange Act of 1934 as information that is officially 'filed' with the SEC. However, investors should still rely on the information it contains for investment decisions.